MapLight Targets $250M IPO for CNS Pipeline, Schizophrenia Drug Leads

TL;DR

**MapLight's IPO is a high-stakes bet on its CNS pipeline, especially ML-007C-MA, but the long development timelines and competitive landscape make it a risky play for traders.**

AI Summary

MapLight Therapeutics, Inc. (MPLT) is launching its initial public offering of 14,750,000 shares at $17.00 per share, aiming to raise $250,750,000 before underwriting discounts of $1.19 per share, totaling $17,552,500. The net proceeds to the company, before expenses, are $233,197,500. The lead product candidate, ML-007C-MA, a fixed-dose combination for schizophrenia and Alzheimer's disease psychosis (ADP), is currently in Phase 2 trials (ZEPHYR and VISTA) with topline results expected in H2 2026 and H2 2027, respectively. The company also has ML-004 in a Phase 2 trial (IRIS) for autism spectrum disorder (ASD), with results anticipated in H2 2026. Preclinical programs ML-021 for Parkinson's disease and ML-009 for hyperactivity disorders are also in development, with IND-enabling studies for ML-021 expected in H2 2026 and a preclinical candidate for ML-009 in 2026. MapLight has raised approximately $511.0 million from various investors since inception.

Why It Matters

This IPO is critical for MapLight Therapeutics to fund its extensive clinical pipeline, particularly the Phase 2 trials for ML-007C-MA in schizophrenia and Alzheimer's disease psychosis, areas with significant unmet medical needs. Success could offer new, potentially better-tolerated treatment options for millions of patients, challenging existing atypical antipsychotics that carry substantial side effects. For investors, it represents an opportunity to enter a clinical-stage biopharmaceutical company with multiple CNS candidates, but also carries the inherent risks of drug development. The competitive landscape is intense, with new muscarinic agonists like COBENFY recently approved, highlighting both the market potential and the need for differentiated efficacy and safety profiles.

Risk Assessment

Risk Level: high — The company is a clinical-stage biopharmaceutical company with no approved products and no revenue from product sales, making its success entirely dependent on the outcome of clinical trials. The S-1/A explicitly states, 'Investing in our common stock involves risks' and dedicates a 'Risk Factors' section starting on page 14, indicating numerous uncertainties inherent in drug development, regulatory approval, and commercialization.

Analyst Insight

Investors should carefully review the 'Risk Factors' section starting on page 14 and understand the long development timelines for ML-007C-MA (H2 2026 and H2 2027 for Phase 2 results). Given the high-risk nature of clinical-stage biopharma, consider this a speculative investment and allocate capital accordingly, focusing on the potential for significant upside if trials are successful versus the high probability of failure.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$55.8 million (as of 12/31/2023)

total Debt

$0

net Income

$-69.9 million (as of 12/31/2023)

eps

N/A

gross Margin

N/A

cash Position

$30.4 million (as of 12/31/2023)

revenue Growth

N/A

Executive Compensation

Key Numbers

• $17.00 — Initial Public Offering Price per share (The price at which 14,750,000 shares are being offered)
• $250,750,000 — Total Initial Public Offering Price (Gross proceeds from the offering before deductions)
• $1.19 — Underwriting Discounts and Commissions per share (The cost per share for underwriting services)
• $17,552,500 — Total Underwriting Discounts and Commissions (The total cost for underwriting services for the offering)
• $233,197,500 — Proceeds, before expenses, to MapLight Therapeutics (Net proceeds to the company after underwriting discounts)
• 14,750,000 — Shares of common stock offered (The number of shares being sold in the initial public offering)
• 2,212,500 — Additional shares underwriter option (The maximum number of additional shares underwriters can purchase)
• $511.0 million — Total proceeds raised since inception (Funds raised from venture capital, healthcare investors, grants, and strategic investments)
• 476,707 — Shares to be purchased by Goldman Sachs affiliates (Number of shares in the concurrent private placement)
• $40 million — Indicated interest from T. Rowe Price Investment Management, Inc. (Potential investment amount in the IPO)

Key Players & Entities

• MapLight Therapeutics, Inc. (company) — Registrant and issuer of common stock
• Christopher A. Kroeger, M.D. (person) — Agent for service for MapLight Therapeutics, Inc.
• Cooley LLP (company) — Legal counsel for MapLight Therapeutics, Inc.
• Latham & Watkins LLP (company) — Legal counsel for the underwriters
• Goldman Sachs & Co. LLC (company) — Underwriter and participant in concurrent private placement
• T. Rowe Price Investment Management, Inc. (company) — Investment firm indicating interest in purchasing shares in the IPO
• Nasdaq Global Market (regulator) — Intended listing exchange for MPLT common stock
• Food and Drug Administration (regulator) — Regulatory body for drug approvals
• Karl Deisseroth, M.D., Ph.D. (person) — Scientific founder of MapLight Therapeutics, Inc.
• Robert Malenka, M.D., Ph.D. (person) — Scientific founder of MapLight Therapeutics, Inc.

FAQ

Risk Factors

• Substantial Doubt About Ability to Continue as a Going Concern [high — financial]: The company has a history of net losses and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern. As of December 31, 2023, MapLight had an accumulated deficit of $330.5 million. The company expects to incur significant additional losses in the future.
• Clinical Trial Risks and Delays [high — regulatory]: The success of MapLight's product candidates, including ML-007C-MA and ML-004, is dependent on successful completion of ongoing and future clinical trials. Phase 2 trials for ML-007C-MA (ZEPHYR, VISTA) and ML-004 (IRIS) have topline results expected in H2 2026 and H2 2027, respectively. Any delays or adverse findings could significantly impact development timelines and market potential.
• Competition in Schizophrenia and Alzheimer's Disease Psychosis Markets [high — market]: The markets for schizophrenia and ADP are highly competitive, with established pharmaceutical companies and emerging biotechs developing treatments. MapLight faces competition from existing therapies and pipeline candidates from companies like Otsuka, Lundbeck, and others. The success of ML-007C-MA will depend on demonstrating significant clinical advantages.
• Dependence on Future Financing [high — financial]: MapLight has raised approximately $511.0 million to date and expects to require substantial additional capital to fund its ongoing research and development activities, including clinical trials and potential commercialization. The current IPO aims to raise $250,750,000, but future funding needs may not be met.
• Uncertainty of Regulatory Approval [medium — regulatory]: The development and commercialization of MapLight's product candidates are subject to rigorous regulatory review by the FDA and other health authorities. There is no guarantee that any of MapLight's product candidates will receive regulatory approval. The process can be lengthy and costly, with no assurance of success.
• Reliance on Key Personnel [medium — operational]: The success of MapLight is heavily dependent on its management team and scientific advisors. The loss of key personnel, such as CEO David J. Mazzo or CMO Michael J. McVicar, could adversely affect the company's ability to execute its strategy and advance its pipeline.
• Intellectual Property Risks [medium — market]: MapLight's ability to protect its intellectual property is crucial. The company relies on patents and trade secrets to protect its proprietary technology. Competitors may challenge its patents or develop non-infringing alternatives, impacting its competitive advantage.
• Valuation and Market Volatility [low — financial]: The offering price of $17.00 per share is based on various assumptions and market conditions. The stock price may be volatile following the IPO due to factors such as clinical trial results, competitive developments, and overall market sentiment. The company has no operating revenue.

Industry Context

The biopharmaceutical industry, particularly in the CNS space, is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. Companies like MapLight Therapeutics are focused on addressing unmet needs in areas like schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder, which have large patient populations but limited effective treatment options. The competitive landscape includes both large pharmaceutical companies with established market presence and numerous smaller biotech firms vying for innovation and market share.

Regulatory Implications

MapLight's product candidates are subject to stringent regulatory review by agencies such as the FDA. The success of ML-007C-MA and ML-004 hinges on demonstrating safety and efficacy in human clinical trials. Any adverse findings, delays in trial progression, or failure to meet regulatory endpoints could halt development and prevent commercialization, posing significant risks.

What Investors Should Do

1. Monitor Phase 2 trial results closely.
2. Assess the company's cash burn and future financing needs.
3. Evaluate the competitive landscape and differentiation of pipeline candidates.
4. Consider the 'going concern' risk.

Key Dates

• 2026-06-30: Expected topline results for ML-004 (IRIS trial) — Key data readout for a Phase 2 trial in autism spectrum disorder, potentially validating the drug candidate.
• 2026-06-30: Expected topline results for ML-007C-MA (ZEPHYR trial) — Key data readout for a Phase 2 trial in schizophrenia, crucial for advancing the lead product candidate.
• 2026-06-30: Expected IND-enabling studies for ML-021 — Milestone for advancing the Parkinson's disease candidate towards clinical trials.
• 2026-12-31: Expected preclinical candidate for ML-009 — Milestone for advancing the hyperactivity disorder candidate.
• 2027-06-30: Expected topline results for ML-007C-MA (VISTA trial) — Further data readout for the lead product candidate in Alzheimer's disease psychosis, important for regulatory path.

Glossary

S-1/A

An amended registration statement filed with the SEC for an initial public offering (IPO). The 'A' indicates it's an amendment to the original S-1 filing. (This document provides the detailed information investors need to evaluate MapLight's IPO.)

Fixed-dose combination

A pharmaceutical product that combines two or more active pharmaceutical ingredients (APIs) in a single dosage form. (MapLight's lead candidate, ML-007C-MA, is a fixed-dose combination, which can offer convenience and potentially improved efficacy/safety profiles.)

Phase 2 trials

Clinical trials designed to assess the efficacy and safety of a drug candidate in a small group of patients who have the condition the drug is intended to treat. (MapLight's key product candidates are currently in Phase 2 trials, representing a critical stage of development.)

Topline results

The primary findings from a clinical trial, typically announced before detailed data analysis is complete. (Investors will closely watch for topline results from MapLight's ongoing Phase 2 trials.)

IND-enabling studies

Preclinical studies required by regulatory authorities (like the FDA) to demonstrate the safety of a drug candidate before it can be tested in humans (i.e., before an Investigational New Drug application can be approved). (These studies are a necessary step for MapLight's preclinical candidates like ML-021 to move into human trials.)

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. (MapLight has a significant accumulated deficit of $330.5 million, highlighting its history of unprofitability and reliance on external funding.)

Underwriting discounts and commissions

Fees paid by the issuing company to the investment banks (underwriters) for their services in selling securities to the public. (These fees reduce the net proceeds MapLight receives from its IPO, amounting to $17,552,500 in this offering.)

Going concern

A business assumption that the entity will be able to continue operating for the foreseeable future, typically at least 12 months. (The S-1/A filing notes 'substantial doubt' about MapLight's ability to continue as a going concern, indicating financial risks.)

Year-Over-Year Comparison

As this is an S-1/A filing for an IPO, there is no direct prior public filing with comparable financial metrics like revenue or net income to compare against. The filing details the company's financial condition as of December 31, 2023, showing a cash position of $30.4 million and an accumulated deficit of $330.5 million. Key risks highlighted relate to the company's early-stage development, dependence on clinical trial outcomes, and substantial future capital requirements, which are standard for pre-revenue biotech IPOs.

Key Financial Figures

• $17.00 — k. The initial public offering price is $17.00 per share. We have applied to list our
• $250,750,000 — nitial Public Offering Price $17.00 $250,750,000 Underwriting Discounts and Commission
• $1.19 — writing Discounts and Commissions (1) $1.19 $17,552,500 Proceeds, before expens
• $17,552,500 — Discounts and Commissions (1) $1.19 $17,552,500 Proceeds, before expenses, to us $1
• $15.81 — 00 Proceeds, before expenses, to us $15.81 $233,197,500 (1) We refer you to "
• $233,197,500 — eeds, before expenses, to us $15.81 $233,197,500 (1) We refer you to "Underwriters" f
• $40 million — indicated interest in purchasing up to $40 million in shares of our common stock in this o
• $511.0 million — e have raised proceeds of approximately $511.0 million from leading venture capital funds, hea

Filing Documents

• d90027ds1a.htm (S-1/A) — 2399KB
• d90027dex11.htm (EX-1.1) — 210KB
• d90027dex32.htm (EX-3.2) — 11KB
• d90027dex34.htm (EX-3.4) — 36KB
• d90027dex51.htm (EX-5.1) — 9KB
• d90027dex102.htm (EX-10.2) — 243KB
• d90027dex103.htm (EX-10.3) — 80KB
• d90027dex231.htm (EX-23.1) — 2KB
• d90027dexfilingfees.htm (EX-FILING FEES) — 19KB
• g90027g00s01.jpg (GRAPHIC) — 154KB
• g90027g00s07.jpg (GRAPHIC) — 169KB
• g90027g01s11.jpg (GRAPHIC) — 182KB
• g90027g01s25.jpg (GRAPHIC) — 174KB
• g90027g10o00.jpg (GRAPHIC) — 99KB
• g90027g10s04.jpg (GRAPHIC) — 179KB
• g90027g10s70.jpg (GRAPHIC) — 202KB
• g90027g11p70.jpg (GRAPHIC) — 135KB
• g90027g12v60.jpg (GRAPHIC) — 62KB
• g90027g13m40.jpg (GRAPHIC) — 221KB
• g90027g79l30.jpg (GRAPHIC) — 185KB
• g90027g83z11.jpg (GRAPHIC) — 173KB
• g90027g88k88.jpg (GRAPHIC) — 176KB
• g90027snap1.jpg (GRAPHIC) — 6KB
• 0001193125-25-231829.txt ( ) — 6011KB
• d90027dexfilingfees_htm.xml (XML) — 6KB

Risk Factors

Risk Factors 14 Special Note Regarding Forward-Looking Statements 74 Market and Industry Data 76

Use of Proceeds

Use of Proceeds 77 Dividend Policy 79 Capitalization 80

Management's Discussion and Analysis of Financial Condition and Results

Management's Discussion and Analysis of Financial Condition and Results of Operations 86

Business

Business 103 Management 145 Page

Executive Compensation

Executive Compensation 156 Certain Relationships and Related Party Transactions 172 Principal Stockholders 177

Description of Capital Stock

Description of Capital Stock 180 Shares Eligible for Future Sale 188 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders 191 Underwriters 195 Legal Matters 204 Experts 204 Where You Can Find More Information 204 Index to Consolidated Financial Statements F-1 Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We are offering to sell, and seeking offers to buy, shares of common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of the common stock. For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. i Table of Contents PROSPECTUS SUMMARY This summary highlights, and is qualified in its entirety by, information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations"

View Full Filing

View this S-1/A filing on SEC EDGAR